Ocular Therapeutix (NSDQ:OCUL) touted interim data today from its phase III trial of Dextenza for the treatment of post-surgical ocular inflammation and pain. The bioresorbable intracanalicular hydrogel plug is designed to release drugs at the ocular surface for up to 30 days.
The company announced last month that Dextenza met the trial’s 2 primary efficacy endpoints: absence of ocular pain after 8 days and lack of inflammation after 2 weeks compared to a placebo. Bedford, Mass.-based Ocular said today that the dexamethasone insert also met its secondary endpoint of absence of ocular flare in the anterior chamber when compared to a placebo. Nearly half of patients in the Dextenza treatment arm had an absence of anterior chamber flare after 4 days following insertion.